News and Announcements
Universal Biosensors (ASX:UBI) CEO Interview
- Published July 08, 2015 4:08PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Universal Biosensors (ASX:UBI) is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use.
UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood.
The first product developed by UBI with LifeScan (a Johnson & Johnson company) is a blood glucose measurement device and is on the market and generating revenues for UBI. The second product developed by UBI in collaboration with Siemens Healthcare has also been launched.
The global point-of-care diagnostics market is estimated to be worth nearly US$17 billion a year and growing.
Please listen to Mr Paul Wright, the CEO of Universal Biosensors.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
